Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.

Abstract	Unlike goserelin, leuprorelin and triptorelin have not been assessed for their impact on survival in patients with locally advanced prostate cancer. The main adverse effects of these two drugs are similar, but convenience of use differs.
Authors
Journal	Prescrire international (Prescrire Int) Vol. 16 Issue 92 Pg. 243 (Dec 2007) ISSN: 1167-7422 [Print] France
PMID	18092407 (Publication Type: Journal Article)
Chemical References	Androgen Antagonists Antineoplastic Agents, Hormonal Triptorelin Pamoate Goserelin Gonadotropin-Releasing Hormone Leuprolide
Topics	Androgen Antagonists (administration & dosage, therapeutic use) Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use) Castration Gonadotropin-Releasing Hormone (administration & dosage, agonists, therapeutic use) Goserelin (administration & dosage, therapeutic use) Humans Leuprolide (administration & dosage, therapeutic use) Male Prostatic Neoplasms (drug therapy) Treatment Outcome Triptorelin Pamoate (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!